Over the past two centuries, humanity has become massively more prosperous, better educated, healthier, and more peaceful.
The underlying cause of this progress is innovation. Human innovation―whether it be new ideas, inventions, or systems―is the primary way people create wealth and escape poverty.
Our upcoming book, Heroes of Progress: 65 People Who Changed the World, explores the lives of the most important innovators who have ever lived, from agronomists who saved billions from starvation and intellectuals who changed public policy for the better, to businesspeople whose innovations helped millions rise from poverty.
If it weren’t for the heroes profiled in this book, we’d all be far poorer, sicker, hungrier, and less free―if we were fortunate enough to be alive at all.
Considering their impact on humanity, perhaps it’s time to learn their story?
Heroes of Progress Book Forum
On March 21st, the author of Heroes of Progress, Alexander Hammond, will present the book live at the Cato Institute in Washington, D.C. He will be joined by Marian Tupy, the editor of Human Progress, and Clay Routledge, the Archbridge Institute’s Vice President of Research, who will speak on the individual’s role in advancing human progress and the need for a cultural progress movement.
Visceral Leishmaniasis Drug Enters Phase II Trial in Ethiopia
“Also known as kala-azar, visceral leishmaniasis is the world’s deadliest parasitic killer after malaria.
It causes fever, weight loss, spleen and liver enlargement, and, if not treated, death. Kala-azar is transmitted by the bite of infected sandflies and is endemic in 80 countries, mainly in Eastern Africa, South Asia, and Latin America. One billion people are at risk globally and Eastern Africa has currently the highest number of cases. As for other vector-borne diseases, climate change is changing the epidemiology of leishmaniasis and could lead to its expansion to new areas. An estimated 50,000 to 90,000 new cases occur worldwide annually, and half are children under 15 years of age.
In Africa, the current treatment for visceral leishmaniasis includes painful injections given at hospital daily for 17 days, a treatment that may also present rare but life-threatening side effects, including to the heart, liver, and pancreas. In contrast, the new molecule under study in Ethiopia, called LXE408, is administered in the form of oral pills and is expected to be safer than the current treatment.”
EU Approves New Antibiotic to Tackle Rise of Superbugs
“The EU has approved a new antibiotic for serious illnesses such as pneumonia and urinary tract infections, marking a step forward in the drive to combat the growing resistance of “superbugs” to existing drugs.
Emblaveo, marketed in Europe by US pharmaceutical company Pfizer, combines two existing medicines to tackle so-called Gram-negative bacteria that are among the leading drug-resistance threats.”
Nigeria Becomes First Country to Roll out New Meningitis Vaccine
“Nigeria has become the first country in the world to roll out the “revolutionary” new Men5CV vaccine against meningitis, the World Health Organization (WHO) said…
The new vaccine is reported to protect against the five major strains of the disease that are prevalent in Nigeria, unlike the initial vaccine that works against only one strain, said the WHO.”
“An early-stage clinical trial yielded promising results for a chlamydia vaccine, researchers reported Thursday in The Lancet Infectious Diseases.
There is currently no vaccine to protect against the sexually transmitted infection, which is the most common bacterial STI in the United States…
The phase 1 clinical trial, led by researchers in the United Kingdom and Denmark, found that the experimental vaccine was safe and induced an immune response.”